CG Oncology Statistics
Total Valuation
CG Oncology has a market cap or net worth of $2.06 billion. The enterprise value is $1.50 billion.
| Market Cap | 2.06B |
| Enterprise Value | 1.50B |
Important Dates
The last earnings date was Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CG Oncology has 66.64 million shares outstanding. The number of shares has increased by 1,158.12% in one year.
| Shares Outstanding | 66.64M |
| Shares Change (YoY) | +1,158.12% |
| Shares Change (QoQ) | +811.42% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,825.32 |
| Forward PS | n/a |
| PB Ratio | 3.62 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,775.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 57.95, with a Debt / Equity ratio of 0.00.
| Current Ratio | 57.95 |
| Quick Ratio | 56.76 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $8,836 |
| Profits Per Employee | -$932,328 |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (1Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 37.14 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.11 |
| Average Volume (30 Days) | 642,349 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CG Oncology had revenue of $539,000 and -$56.87 million in losses. Loss per share was -$0.85.
| Revenue | 539,000 |
| Gross Profit | n/a |
| Operating Income | n/a |
| Pretax Income | n/a |
| Net Income | -56.87M |
| EBITDA | n/a |
| EBIT | n/a |
| Loss Per Share | -$0.85 |
Balance Sheet
The company has $566.51 million in cash and $404,000 in debt, giving a net cash position of $566.10 million or $8.49 per share.
| Cash & Cash Equivalents | 566.51M |
| Total Debt | 404,000 |
| Net Cash | 566.10M |
| Net Cash Per Share | $8.49 |
| Equity / Book Value | 568.94M |
| Book Value Per Share | 8.54 |
| Working Capital | 568.63M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | -10,551.39% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CG Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,158.12% |
| Shareholder Yield | -1,158.12% |
| Earnings Yield | -2.76% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CG Oncology is $63.75, which is 105.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $63.75 |
| Price Target Difference | 105.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 346.09% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |